Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Western medicine for treating type II diabetes

A technology of diabetes and western medicine, applied in the field of biopharmaceuticals, can solve the problems of small intestinal mucosal cell damage, shock, weight loss, etc., and achieve a good synergistic effect

Pending Publication Date: 2020-06-30
LIAONING INST OF SCI & TECH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, metformin absorbs rapidly, has a short half-life, and takes only 2 to 4 hours. It needs to be taken 2 to 3 times a day, resulting in large fluctuations in blood drug concentration in the body. Long-term use of this type of drug will cause certain damage to the small intestinal mucosal cells. damage, accompanied by symptoms such as weight loss
[0005] Moreover, the above types of drugs have weak hypoglycemic effect when taken alone. If the above drugs can be used in combination, the effect of hypoglycemia may be improved. However, due to the different release targets of the above drugs, when they are used in combination, they will cause hypoglycemia. , fatigue and even shock

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Western medicine for treating type II diabetes
  • Western medicine for treating type II diabetes
  • Western medicine for treating type II diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] A preparation method of western medicine for the treatment of type II diabetes, comprising the steps of:

[0022] 1) Weighing: Weigh 25% of sitagliptin, 30% of dapagliflozin and 45% of gliquidone according to the mass ratio, and set aside;

[0023] 2) Mixing: Grinding and mixing the obtained sitagliptin, dapagliflozin and gliquidone to obtain a mixture;

[0024] 3) Tableting: Compress the mixture into tablets with a diameter of 0.85 cm.

Embodiment 2

[0026] 1) Weighing: Weigh vildagliptin 35%, empagliflozin 40% and gliquidone 25% according to the mass ratio, and set aside;

[0027] 2) Mixing: Grinding and mixing the obtained vildagliptin, empagliflozin and gliquidone to obtain a mixture;

[0028] 3) Tableting: Compress the mixture into tablets with a diameter of 0.85 cm.

Embodiment 3

[0030] 1) Weighing: Weigh 30% of saxagliptin, 35% of empagliflozin and 35% of gliquidone according to the mass ratio, and set aside;

[0031] 2) Mixing: pulverize and mix the obtained saxagliptin, empagliflozin and gliquidone to obtain a mixture;

[0032] 3) Tableting: Compress the mixture into tablets with a diameter of 0.85 cm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Login to View More

Abstract

The present invention discloses a western medicine for treating type II diabetes. Active ingredients of the western medicine comprise the following raw materials in mass percentages: 25-35% of a DPP4inhibitor, 30-40% of a SGLT2 inhibitor and 25-45% of gliquidone. The DPP4 inhibitor, SGLT2 inhibitor and gliquidone are compounded, blood sugar level is significantly reduced, and besides, the compounded medicine can effectively relieve symptoms and pathological phenotypes of diabetic nephropathy and reduce production of urine proteins in urine of patients.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to a western medicine for treating type II diabetes. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by hyperglycemia, mainly caused by defects in insulin secretion or its biological action, or both. Long-term hyperglycemia can lead to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves. Due to the large number of diabetic patients and the poor quality of life after the disease, it has gradually become one of the increasingly serious public health problems. Due to the decline of physical function and resistance, the elderly group has become a high-risk group of diabetes. [0003] In patients with type II diabetes, hepatic gluconeogenesis and damage to pancreatic B cells affect the normal secretion of insulin. Therefore, at present, the drugs used to treat diabetes are main...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/64A61P3/10
CPCA61K31/64A61K45/06A61P3/10A61K2300/00
Inventor 张颖
Owner LIAONING INST OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com